Income Statement
ACUMEN PHARMACEUTICALS, INC.
ABOS
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
123.83 | 114.02 | 61.14 | 45.24 | 19.58 |
|
Research & Development
|
104.89 | 93.80 | 42.32 | 32.36 | 12.31 |
|
Selling, General & Administrative
|
18.95 | 20.22 | 18.82 | 12.88 | 7.28 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-123.83 | -114.02 | -61.14 | -45.24 | -19.58 |
|
Non-Operating Income
|
2.50 | 11.69 | 8.77 | 2.38 | -81.02 |
|
Interest Income
|
7.45 | 14.32 | 10.79 | - | - |
|
Interest Expense
|
4.22 | 4.06 | 0.58 | - | - |
|
Other Non-Op Income / Expense
|
-0.27 | -0.15 | -0.08 | -0.01 | 0.05 |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-121.34 | -102.33 | -52.37 | -42.86 | -100.61 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-123.83 | -114.02 | -61.14 | -45.24 | -19.58 |
|
Earnings Per Share (Basic)
|
-2.00 | -1.71 | -1.08 | -1.06 | - |
|
Diluted EPS
|
-2.00 | -1.71 | -1.08 | -1.06 | - |
|
Weighted Average Shares
|
60.56 | 60.01 | 48.61 | 40.60 | - |
|
Diluted Weighted Avg Shares
|
60.56 | 60.01 | 48.61 | 40.60 | - |
|
Comprehensive Income
|
-121.20 | -102.69 | -51.31 | -43.38 | - |